CURRICULUM VITAE
June, 2010

David M. Shlaes MD Ph.D.

PERSONAL DATA:

Place of Birth	Chicago, IL
Marital status	Married, two children
Present home address	219 Montauk Ave., Stonington, CT 06378
Telephone (home)	+1-860-535-1505
(mobile)	+1-617-669-8364
e-mail –	shlaes.david@earthlink.net
Citizenship	USA

EDUCATION:

1965-1969	BA, Biology-Chemistry (Magna cum laude) Lawrence University Appleton, Wisconsin
1969-1975	Ph.D., Microbiology Case Western Reserve University Cleveland, OH
1969-1976	MD Case Western Reserve University Cleveland, OH

PROFESSIONAL EXPERIENCE:

Sole Proprietor and President – Anti-Infectives Consulting, LLC. 2005-present

Independent Director, Board of Directors, Novexel S.A, Romainville, France. 2006-2010.

Senior Fellow, Idenix Pharmaceuticals, 2004-2005

Executive Vice President, Research and Development, Idenix Pharmaceuticals, Inc., 2002-4

Therapeutic Area Co-Leader for Infectious Diseases, Wyeth-Ayerst, Feb. 2000 – 2002

Vice President, Infectious Diseases, Wyeth Ayerst Research 1996-2002	
Chief, Infectious Diseases Section 1984-1991	VA Medical Center Cleveland, OH
Chief, Clinical Microbiology Unit 1980-1994	VA Medical Center Cleveland, OH
Clinical Investigator, 1990-1996	Department of Veterans Affairs
Professor of Medicine, 1991	Case Western Reserve University School of Medicine
Award of Tenure, 1988	Case Western Reserve University School of Medicine Cleveland, Ohio
Associate Professor of Medicine 1986-1991	Case Western Reserve University School of Medicine Cleveland, OH
Assistant Professor of Medicine 1980-1986	Case Western Reserve University School of Medicine Cleveland, OH
Chief Resident (Medicine) 1979-80	Mt. Sinai Hospital Cleveland, OH
Fellow (Infectious Diseases) 1978-89	Cleveland Metropolitan General Hospital (with Dr. E. Wolinsky) Cleveland, OH
Resident (Medicine) 1977-88	Mt. Sinai Hospital Cleveland, OH
Intern (Medicine) 1976-77	Mt. Sinai Hospital Cleveland, OH

MEDICAL LICENSURE:

Ohio 1976-1996
New Jersey – 1997 – 2005
Connecticut – 2006-present

SOCIETIES AND ASSOCIATIONS:

Diplomate, National Board of Medical Examiners
Diplomate, American Board of Internal Medicine
American Society for Microbiology
Infectious Diseases Society of America, Fellow, 1992
Elected member, Central Society for Clinical Research, 1989.
Society of Hospital Epidemiologists of America, 1994.

CAREER GOALS: I still am highly motivated to bring new anti-infective therapies to the market which provide value to patients, physicians and industry, while preserving a degree of independence for myself and time for my family.

CURRENT RESPONSIBILITIES: I began a consulting business in the area of antiinfective discovery, development, and strategic planning. I am currently self-employed. In my new role, I have several major clients. **I have been an independent director for Novexel SA headquartered in France that was just sold to Astra-Zeneca for $505 million.** I have a number of clients for whom I have smaller time commitments. They include both investment firms and biotechnology companies in Europe, and the US. My roles for all these clients involve some work in the drug discovery area, but mostly in translational research and strategic planning of Ph I-III clinical trials and in business development. I filled in as interim CSO for one client during a one-year recruitment effort. I have carried out a number of evaluations for investment firms, some of which have progressed to due diligence and beyond. My prior experience leading the Infectious Diseases Therapeutic Area at Wyeth and later as Executive Vice President for Research and Development at Idenix Pharmaceuticals where I was also responsible for manufacturing for a period of time provided valuable experience in both large PhRMA and biotech. The projects included anti-bacterials and anti-virals at all stages of research and development. I have had reasonably extensive experience with the FDA including work with the PhRMA Antimicrobial Working Group to bring together industry, the Infectious Diseases Society of America and the FDA around the topic of clinical trial design in anti-infectives. This breadth of experience has been invaluable to me in my current role.

RESPONSIBILITIES AT IDENIX 11/04 – 10/05: I worked on a part time basis where I continued to lead the pharmacology-toxicology group in support of Idenix development programs. I also played a lead role in a naiscent biodefense effort at Idenix. I still reported directly to the CEO.

RESPONSIBILITIES AT IDENIX 2002-4:

At Idenix, I led a team including biologists, chemists, process chemists, toxicologists and pharmacologists to identify and develop novel anti-infective compounds in areas of

important medical need. Idenix scientists are located in Cambridge, MA, Montpellier, France and Cagliari, Italy. For the first year at Idenix, I also had primary responsibility for API manufacturing and Drug Product manufacturing. My responsibilities at Idenix were much broader than those I had at Wyeth. At Idenix, as Executive Vice President for Research and Development, I reported directly to the CEO and interacted closely with the CFO, Business Development, Legal and Patent Counsel. During my tenure as EVP at Idenix, I:

Led the preparation of our IND for NM283, our nucleoside analog for the treatment of Hepatitis C virus infection for which development was halted after Ph. II.

Led the Idenix effort in **Biodefense**. This effort has led to the submission of a response to an RFP from NIAID with a budget of $500MM which was submitted for funding. I helped prepare this submission with the Memphis Bioworks Foundation who have taken over primary responsibility for the project.

Had primary responsibility for all preclinical activities, from toxicological testing, preclinical pharmacokinetics, to API and drug product manufacturing for NM283.

Initiated preclinical studies to support the development of LdC-LdT combination and to support the ultimate NDA for LdT planned for 2005. The preclinical development plan for LdT-LdC, which was accepted by the FDA, was unique since it involved a fixed combination of two, as yet unapproved, drugs.

RESPONSIBILITIES AND ACCOMPLISHMENTS AT WYETH 1996-2002:

My goal at Wyeth was to discover and lead the pre-clinical development of innovative anti-bacterial and anti-viral compounds to fill areas of clear medical need and which are of significant commercial value. To achieve this goal, I directed a team of about 70 biologists and biochemists (~50% Ph.D.s:non-Ph.D.s) and a number of multidisciplinary project teams. I also directed our Natural Products Microbiology group (~20 FTEs), a central resource within Wyeth. I reported to the SVP for Discovery who, in turn, reported to the President, R&D.

During my tenure at Wyeth, I:

Led the strategic planning process for Infectious Diseases at Wyeth-Ayerst Research.

Delivered one anti-bacterial to clinical development, tigecycline. I helped design its Ph. II and III trials. It is now launched as Tygacil. One antiviral was delivered in March, 1999 a second, in partnership with ViroPharma, was delivered early in 2000 and a third in 2002.

Established a major alliance with Chem-Genics (which became part of Millennium Pharmaceuticals) for the discovery of novel, essential bacterial gene targets.

Established an alliance with Dr. Vincent Fischetti of Rockefeller University, Dr. Olaf Schneewind of the University of Chicago and SIgA Pharmaceuticals for screening a protease involved in the expression of bacterial proteins on the cell surface. Inhibitors of this enzyme should lead to loss of virulence by attacking a number of virulence factors simultaneously.

Established an alliance with Dr. Piet DeBoer and Case Western Reserve University for identifying inhibitors of a novel bacterial cell division protein.

Established a major alliance with ViroPharma for the Discovery and Development of compounds active against Hepatitis C Virus.

Strengthened our antiviral research program, improved our level of automation for secondary assays, and reorganized the infectious disease research section to increase synergies between anti-viral and anti-bacterial research and our overall efficiency.
Participated in an important task force which resulted in a major alteration in our Discovery process to bring Development resources in at a very early stage. Results two years after implementation of this process indicate a reduced time to development track and a reduced Ph. 0/I drop-out rate.
Acquired responsibility for Natural Products Microbiology.
Supervised about 90 scientists.
Was instrumental in convincing the FDA that their planned increase in clinical trial design stringency, as conceived, would drive industry out of antibiotic discovery and development – they reversed their decision (temporarily) as a result.

BOARD OF DIRECTORS:

Novexel, SA, Romainville, France. Independent Director.

SCIENTIFIC ADVISORY BOARDS:

Novexel
Nabriva
J&J
Others . . .

LANGUAGE SKILLS:

Working knowledge of written and spoken French.

EDITORIAL RESPONSIBILITIES:

Editor, Antimicrobial Agents and Chemotherapy, 2010-2015.
Editorial Board, J Clin Microbiol, 1983-5
Editorial Board, Antimicrobial Agents and Chemotherapy, 1986- present, Clinical Microbiology and Infection, 1995-present, Drugs in R&D, 1998-2000.
Ad hoc reviewer for: New Engl J Med, J Infec Dis, Clin Infec Dis, Arch Intern Med, Ann Intern Med., Chest.

NATIONAL GRANT REVIEWING RESPONSIBILITIES:

Infectious Diseases Merit Review Board, Veterans Administration Central Office - 1992-5.
Ad hoc reviewer for: American Heart Association (Northeast Ohio Branch), National Science Foundation, National Institutes of Health.
Member, Special Study Section, Biology of *Mycobacterium tuberculosis*, NIAID, 1993.
Member, Special Study Section, Regional Centers for Excellence in Biodefense, 2004, 2005.

COMMITTEE RESPONSIBILITIES:

ICAAC Committee, 1989 - 1993.
Chairman, Division L, Nosocomial Infections, of the American Society for Microbiology, 1988.

Chair-elect, Division L, Nosocomial Infections, of the American Society for Microbiology, 1987.
Program Committee, Annual Meeting, American Thoracic Society, 1986.
Planning Committee, Mechanisms of Infection Teaching Committee, Case Western Reserve University School of Medicine, 1985-1994.
Chairman, Mechanisms of Infection Teaching Committee, CWRU School of Medicine, 1988-1993.
Chairman, Infection Control Committee, Cleveland VAMC, 1982-1996.
Member, Research and Development Committee, Cleveland VAMC, 1989-1990.
Chairman, Research and Development Committee, Cleveland VAMC, 1990- 1992.
Member, American Society for Microbiology Task Force on Antimicrobial Resistance, 1994.
Program Committee, Annual Meeting of the Infectious Diseases Society of America - 1996-1999.
Member, Institute of Medicine Forum on Emerging Infections, National Academy of Sciences, 1996-2003.
Consultant, Multi-Agency Task Force on Combatting Antibiotic Resistance, 1999.
Chairman, SHEA Antibiotics Committee, 1994 – 1996.
Member, PhRMA Antibiotics Working Group, 2001-2005.
Member, Infectious Diseases Society Taskforce on Antimicrobial Resistance, 2003-2007.
Participant, NIAID Summit, 2004.
Member, Manhattan Institute, Project for FDA Reform, 2004-2007

HONORS:

Sabbatical leave to study mechanisms of resistance to glycopeptide antibiotics at the University of Paris with Dr. J. Acar, 1987-8.
Chairman, Organizing Committee, NIH Workshop to define New Research Directions in Antimicrobial Resistance, 1990. Follow-up meeting NIAID, CDC, FDA, Jan. 1992.
Participant, FDA Symposium on Antimicrobial Residues in Food. June, 1992.
Visiting Professor:
U. Pittsburgh, Department of Medicine, September, 1992.
Columbia College of Medicine, November, 1992.
SUNY Buffalo, 1996.
Distinguished Lecturer, MD-Ph.D. Program, University of Cincinnati School of Medicine, 1998.
Interviewed by Science, April, 1994.
Television interviews on Antimicrobial Resistance, ABC News, 1994.
Professeur Associé, Université de Paris VI, Année sabbatique, 1994-5.
American Society for Microbiology Foundation Lecturer 1996-98.
Cover story and photograph - Business Week, April 6, 1998.
Discover Magazine Interview – 1998.
Fortune Magazine Interview – July, 2002

PhRMA presentation to FDA at Workshop on clinical trial design in infectious diseases 2000, 2001.

2006 – Gordon Research Conference on New Antibacterial Discovery and Development, ASM annual Meeting, ICAAC.

RESEARCH SUPPORT:

Continuous funding by the NIH or the VA Central Office 1984 - 1996.

BIBLIOGRAPHY:

Ph.D. Thesis

Shlaes DM. Recombination repair in *Escherichia coli* K12. Case Western Reserve University School of Medicine, Department of Microbiology, September, 1975.

Books

Shlaes, DM. Antibiotics – The Perfect Storm. Springer-Verlag, In Press, 2010.

PUBLICATIONS (In Refereed Journals):

1. **Shlaes** DM, Anderson JA and Barbour SD. Excision repair properties of isogenic *rec*$^-$ mutants of *Escherichia coli* K12. J. Bacteriol 111:723-730, 1972.

2. **Shlaes** DM and Barbour SD. Repair of UV damaged DNA in *sbcA* strains of *Escherichia coli* K12. J Bacteriol 138:105-8, 1979.

3. **Shlaes** DM, Levy J and Wolinsky E. Enterococcal bacteremia without endocarditis. Arch Intern Med 141:578-581, 1981.

4. **Shlaes** DM, Lerner PI, Wolinsky E and Gopalakrishna KV. Infections due to Lancefield group F and related streptococci (*S. milleri* and *S. anginosus*). Medicine 60:197-207, 1981.

5. **Shlaes** DM, Dul MJ and Lerner PI. *Anaerobiospirilum* bacteremia. Ann Intern Med 97:63-4, 1982.

6. **Shlaes** DM, Dul MJ and Lerner PI. *Capnocytophaga* bacteremia in the compromised host. Am J Clin Pathol 77:359-361, 1982.

7. **Shlaes** DM, Mandell R, Bass SN and Spagnuolo PJ. Bacteremia due to *Streptococcus pneumoniae* of non-vaccine serotypes. Am Rev Resp Dis 126:712-3, 1982.

8. Knight RG and **Shlaes** DM. Rapid identification of *Staphylococcus aureus* and *Streptococcus pneumoniae* from blood cultures. J Clin Microbiol 17:97-9, 1983.

9. **Shlaes** DM, Lederman M, Chmielwski R et. al. Elastin fibers in the sputum of patients with necrotizing pneumonia. Chest 83:885-9, 1983.

10. King CH, **Shlaes** DM and Dul MJ. Infection due to thymidine-requiring trimethoprim-resistant bacteria. J Clin Microbiol 18:79-83, 1983.

11. **Shlaes** DM, Currie CA, Rotter G, Eanes M and Floyd R. The epidemiology of gentamicin-resistant Gram negative bacilli on a spinal cord injury unit. J Clin Microbiol 18:227-235, 1983.

12. **Shlaes** DM and Currie CA. Endemic gentamicin-resistance R-factors on a spinal cord injury unit. J Clin Microbiol 18:236-241, 1983.

13. Vartian CV and **Shlaes** DM. Intravenous acyclovir and neurologic effects. (Letter). Ann Intern Med 99:568, 1983.

14. Dul MJ, **Shlaes** DM and Lerner PI. EF-4 bacteremia in a patient with hepatic carcinoid. J Clin Microbiol 18:1260-1261, 1983.

15. **Shlaes** DM, Vartian CV and Currie CA. Variability in DNA sequence of closely related nosocomial gentamicin-resistance plasmids. J Infect Dis 148:1013-8, 1983.

16. Barbour SD, **Shlaes** DM and Guertin SR. Toxic shock syndrome associated with nasal packing: analogy to tampon-associated illness. Pediat 73:163-5, 1984.

17. Knight RG and **Shlaes** DM. One hour litmus milk test for identification of Streptococcus faecalis from blood cultures. Lab Med 15:417-8, 1984.

18. **Shlaes** DM, Marino J and Jacobs MR. Infection caused by a vancomycin-resistant *Streptococcus sanguis II*. Antimicrobial Agents and Chemother 25:527-8, 1984.

19. **Shlaes** DM, Lederman MM, Chmielewski R, et. al. Sputum elastin fibers in the diagnosis of necrotizing pneumonia. Chest 85:763-6, 1984.

20. Knight RG, **Shlaes** DM and Mesineo L. DNA relatedness of some human enterococci. Internat J Systemat Bacteriol 34:327-331, 1984.

21. **Shlaes** DM, Toosii Z and A. Patel. Direct Lancefield grouping of streptococci from blood cultures: Comparison of latex agglutination and immunofluorescence. J Clin Microbiol 20:195-198, 1984.

22. Vartian CV, Lerner PI, **Shlaes** DM, and Gopalakrishna KV. Infections due to Lancefield group G streptococci. Medicine 64:75-88,1985.

23. Vartian CV, **Shlaes** DM, Padhye AA and Ajello L. *Wangiella dermatidis* endocarditis in an intravenous drug user. Am J Med 78:703-7, 1985.

24. Knight RG and **Shlaes** DM. Physiologic and deoxyribonucleic acid relatedness of *Streptococcus bovis* and *Streptococcus bovis* (variant). Internat J Systemat Bacteriol 35:357-361, 1985.

25. Knight RG and **Shlaes** DM. DNA relatedness of *Enterococcus hirae* and "*Streptococcus durans*" (homology group II). Internat J Systemat Bacteriol 36:111-113, 1986.

26. Kasmer RJ, Walker N, Hurlburt F, Rotter G, **Shlaes** DM and Hostetler C. Sterility of preloaded insulin syringes. Am J Infec Cont, 14:180-3, 1986.

27. **Shlaes** DM, Medeiros AA, Kron MA, Currie-McCumber CA and Vartian CV. A novel plasmid-mediated β-lactamase in *Enterobacteriaceae* from Ohio. Antimicrob Agents and Chemother, 30:220-224, 1986.

28. Jacobs MR, Aronoff SC, Johenning S, **Shlaes** DM and Yamabe T. Comparison of the β−lactamase inhibitors YTR-830, clavulanic acid and sulbactam combined with β−lactams against Gram negative bacilli with defined -β−lactamases. Antimicrob Agents and Chemother 29:980-5, 1986.

29. **Shlaes** DM, Currie-McCumber CA, Eanes M et. al. Gentamicin-resistance plasmids in an intensive care unit. Infec Cont 7:355-361,1986.

30. **Shlaes** DM and Currie-McCumber CA. Dissemination of a plasmid determining multiple antibiotic resistance between two Veterans Administration Medical Centers. Infec Cont 7:362-4, 1986.

31. **Shlaes** DM, Lehman MH, Currie-McCumber CA and Kim CH. Endemic multiply antibiotic resistant *Enterobacteriaceae* on a nursing home care unit: The importance of cross-infection as determined by plasmid analysis. Infec Cont, 7:538-545, 1986.

32. Rhinehart E, **Shlaes** DM, Serkey J, Keys T, et. al. Clonal dissemination of methicillin-resistant *Staphylococcus aureus* (MRSA) identified by plasmid analysis. Arch Intern Med 147:521-4, 1987.

33. Salata R, Lederman M, **Shlaes** DM et. al. Nosocomial pneumonia: A prospective study of intubated patients. Am Rev Resp Dis 135:426-432, 1987.

34. Aronoff SC and **Shlaes** DM. Factors which influence the development of β-lactam resistance in -lactamase inducible strains of *Enterobacter cloacae* and *Pseudomonas aeruginosa*. J Infec Dis, 155:936-941, 1987.

35. Catto B, **Shlaes** DM, Jacobs MR. *Streptococcus mitis*: A cause of serious infection in adults. Arch Intern Med, 147:885-888, 1987.

36. Sliman R, Rehm S and **Shlaes** DM. Serious infections caused by *Bacillus species*. Medicine 66:218-223, 1987.

37. **Shlaes** DM, Yessayan A and Currie-McCumber CA. The VA ANT(2") plasmid found in Dallas, Texas. Letter to the editor, Antimicrob Agents and Chemother, 31:1155, 1987.

38. Kron MA, Currie-McCumber CA, Medeiros AA and **Shlaes** DM. The molecular epidemiology of the OHIO-1 β-lactamase. Antimicrob Agents and Chemother, 31:2007-9, 1987.

39. Knight RG and **Shlaes** DM. Physiological Characteristics and Deoxyribonucleic Acid relatedness of *Streptococcus intermedius* strains. Internat J Systemat Bacteriol, 38:19-24, 1987.

40. Fry DE, Fry RV and **Shlaes** DM. Serratia bacteremia in the surgical patient. Am Surg 53:438-441, 1987.

41. MacArthur R, Lehman MH, Currie-McCumber CA and **Shlaes** DM. The epidemiology of gentamicin resistant *Pseudomonas aeruginosa* on an intermediate care ward. Am J Epidemiology 128:821-827, 1988.

42. **Shlaes** DM and Little J. Cefoxitin-aztreonam antagonism does not correlate with induction of β–lactamase. J Antimicrob Chemother 21:673-675, 1988.

43. **Shlaes** DM, Lehman MH and Currie-McCumber CA. Endemic plasmid encoding the OHIO-1 β–lactamase on an intermediate care ward. Infection Control and Hospital Epidemiology 9:317-319, 1988.

44. **Shlaes** DM, Bouvet A, Devine C, Shlaes JH, Al-Obeid S and Williamson R. Inducible, transferable resistance to vancomycin in *Enterococcus faecalis* A256. Antimicrobial Agents and Chemother, 33:198-203, 1989.

45. Williamson R, Al-Obeid S, Shlaes JH, Goldstein FW and **Shlaes** DM. Inducible resistance to vancomycin in *Enterococcus faecium* D366. J. Infect Dis 159:1095-1104, 1989.

46. **Shlaes** DM, Al-Obeid S, Shlaes JH and Williamson, R. Activity of glycopeptides against a glycopeptide resistant strain of *Enterococcus faecium*, D366. J. Infect Dis 159:1132-1135, 1989.

47. **Shlaes** DM, Shlaes JH, Davies JD and Williamson R. *Escherichia coli* susceptible to some glycopeptides. Antimicrob Agents and Chemother, 33:192-197, 1989.

48. **Shlaes** DM, Al-Obeid S, Shlaes JH, Boisivon H and Williamson R. Inducible, transferable resistance to vancomycin in *Enterococcus faecium* D399. J Antimicrob Chemother, 32:503-508, 1989.

49. Salata R, Lerner PI, **Shlaes** DM and Wolinsky E. Serious infections caused by group C streptococci. Medicine, 68:225-239, 1989.

50. Wiest PM, Flanigan T, Salata RA, **Shlaes** DM et. al. Serious infectious complications of corticosteroid therapy for COPD. Chest, 95:1180-1184, 1989.

51. Cooper G, Havlir D, **Shlaes** DM, Salata R. Polymicrobial Bacteremia. Medicine 69:114-123,1990.

52. **Shlaes** DM, Currie-McCumber CA, Hull A and Kron M. The OHIO-1 β–lactamase is related to SHV-1, LEN-1 and TEM. Antimicrob Agents and Chemother, 34:1570-1576,1990.

53. Al-Obeid S, Gutmann L, **Shlaes** DM, Williamson R and Collatz E. Comparison of vancomycin-inducible proteins from four strains of enterococci. FEMS Microbiol Lett, 70:101-106, 1990.

54. **Shlaes** DM, Etter LM and Gutmann L. Synergistic killing of vancomycin-resistant enterococci of phenotypic classes A, B and C by combinations of vancomycin, penicillin and gentamicin. Antimicrob Agents and Chemother, 35:776-9, 1991.

55. Chow JW, Fine MJ, **Shlaes** DM, et. al. *Enterobacter* Bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Int Med, 115:585-590, 1991.

56. Chow JW and **Shlaes** M. Imipenem resistance associated with the loss of a 40 kDa outer membrane protein in *Enterobacter aerogenes*. J Antimicrob Chemother, 28:499-504, 1991.

57. Vincent S, Knight RG, Green M, Sahm DF, and **Shlaes** DM. Vancomycin susceptibility and Identification of Motile Enterococci. J Clin Microbiol, 29:2335-2337, 1991.

58. **Shlaes** DM and Currie-McCumber CA. Mutations altering substrate specificity in OHIO-1, a SHV family β–lactamase. Biochem J 284:411-415, 1992.

59. Vincent S, Minkler, P., Bincziewski B., Etter L. and **Shlaes** DM. Vancomycin resistance in *E. gallinarum*. Antimicrob Agents and Chemother 36:1392-1399, 1992.

60. Bonomo RA, Currie-McCumber CA and **Shlaes** DM. OHIO-1 β–lactamase resistant to mechanism-based inactivators. FEMS Microbiol Lett 92:79-82, 1992

61. Wingart E, Shlaes JH, Mortimer EA and **Shlaes** DM. Evidence for nursing hand mediated transmission of trimethoprim-resistant Gram negative bacilli on a nursing home. Clinical Infect Dis, 16:75-81, 1993.

62. Cooper GS, **Shlaes** DM, Jacobs MR and Salata RA. The role of enterococcus in intraabdominal infections: A case control analysis. Infect Dis in Clin Pract 2:332-339, 1993

63. Green M, Binczewski B, Pasculle AW,Edmund M, Barbadora K, Kusne S and **Shlaes** DM. Constitutively vancomycin-resistant *Enterococcus faecium* resistant to synergy with Beta-lactams. Antimicrobial Agents and Chemother, 37:1238-1242, 1993.

64. Rice LB, **Shlaes** DM and Carias L. Efficacy of ampicillin/sulbactam versus cefoxitin in the treatment of *Escherichia coli* infections in the rat intra-abdominal abscess model. Antimicrobial Agents and Chemother. 37:610-612, 1993.

65. Rice LB, Carias L and **Shlaes** DM. Resistance to cefoperazone-sulbactam in *Klebsiella pneumoniae*: Evidence for enhanced resistance resulting from the coexistence of two different resistance mechanisms. Antimicrobial Agents and Chemother. 37:1061-1064, 1993.

66. Chow JW, Kuritza A, **Shlaes** DM, Green M, Sahm DF and Zervos MJ. Clonal spread of vancomycin-resistant *Enterococcus faecium* between patients in three hospitals in two states. J Clin Microbiol, 31:1609-11, 1993.

67. **Shlaes** DM, Shlaes JH, Vincent S, Fey PD and Goering RV. Teicoplanin-resistant *Staphylococcus aureus* expresses a novel membrane protein and increases expression of Penicillin-Binding Protein 2 complex. Antimicrobial Agents and Chemother 37:2432-2437, 1993.

68. Chow JW, Yu VL, and **Shlaes** DM. Epidemiologic Perspectives on Enterobacter for the Infection Control Practioner. American Journal of Infection Control, 22:195-201, 1994.

69. Higashi J, Wang I-W, **Shlaes** DM and Marchant RE. The adhesion of *Staphylococcus epidermidis* and transposon mutant strains to hydrophobic NHLBI polyethylene. Trans Soc Biomater 20:366, 1994.

70. **Shlaes** DM, Norden C., et. al. Piperacillin-tazobactam versus Ticarcillin-clavulanate in the treatment of community-acquired lower respriatory infection. J. Antimicrob Chemother. 34:565-577, 1994.

71. Cooper GS, **Shlaes** DM and Salata RA. Intraabdominal infections in the elderly: Differences in presentation and outcome. Clin Infect Dis. 19:146-8, 1994.

72. Rice LB, Carias LL and **Shlaes** DM. In vivo efficacy of β-lactam/β-lactamase inhibitor combinations against a TEM-26 producing strain of *Klebsiella pneumoniae*. Antimicrob Agents and Chemother, 38:2663-4, 1994.

73. Donabedian S, Chow JW, **Shlaes** DM, Green M, and Zervos MJ. DNA Hybridization and contour clamped homogeneous Electric Field (CHEF) Electrophoresis for Speciation of Enterococci. J Clin Microbiol, 33:141-5, 1995.

74. Bonomo RA, Knox JR, Dawes C and **Shlaes** DM. The role of M69 and G242 in OHIO-1, a class A beta lactamase of the SHV family. Biochim Biophys Acta, 1247:113-120, 1995.

75. Bonomo RA, Knox JR, Dawes, C and **Shlaes** DM. β-lactamase mutations far from the active site influence inhibitor binding. Biochim Biophys Acta, 1247:121-125, 1995.

76. Green, Shlaes JH, Barbadora K and **Shlaes** DM. Bacteremia due to Vancomycin-dependent *Enterococcus faecium*. Clin Infec Dis 20:712-714, 1995.

77. Mainardi, JL, **Shlaes** DM, Goering RV, Shlaes JH, Acar JF, Goldstein FW. Decreased teicoplanin susceptibilty of Methicillin-Resistant Strains of *Staphylococcus aureus*. J Infect Dis. 171:646-50, 1995.

78. **Shlaes** DM and Shlaes JH. Teicoplanin selects *Staphylococcus aureus* resistant to vancomycin. Clinical Infect Dis, 20:1071-1073, 1995.

79. Rice LB, Carias LL, Bonomo RA and **Shlaes** DM. Ceftazidime-resistant *Klebseilla penumoniae* at a Department of Veterans Affairs Medical Center II: Genetic analysis and response to therapy of strains resistant to both ceftazidime and β−lactam- β−lactamase inhibitor combinations. J Infec Dis. 173:151-8, 1996.

80. Rice LB, Eckstein E, DeVente J and **Shlaes** DM. Ceftazidime-resistant *Klebseilla penumoniae* at a Department of Veterans Affairs Medical Center I: Description of the outbreak, clinical significance and response to replacement of ceftazidime with piperacillin-tazobactam. Clin Infect Dis 23:118-124, 1996.

81. Billot-Klein D, **Shlaes** DM., Bryant D, Bell D, van Heijenoort J and Gutmann L. Peptidoglycan structure of *E. faecium* expressing resistance of the VanB type. Biochem J., 313:711-715, 1996.

82. Billot-Klein D, Gutmann L, Bryant D, Bell D, van Heijenoort J, Grewal J and **Shlaes** DM. Peptidoglycan synthesis and structure in *Staphylococcus hemolyticus* expressing increasing levels of resistance to the glycopeptide antibiotics. J. Bacteriol 178:4696-4703, 1996.

83. Scott JAG. Hall AJ. Dagan R. Dixon JMS. Eykyn SJ. Fenoll A. Hortal M. Jette LP.Jorgensen JH. Lamothe F., Latorre C., Macfarlane JT., **Shlaes** DM., Smart LE., Taunay A. Serogroup-specific epidemiology of *Streptococcus pnuemoniae* - Associations with sex, and geography in 7,000 episodes of invasive disease. Clinical Infectious Diseases. 22:973-981, 1996.

84. Truong QC, Nguyen JC, **Shlaes** DM, Gutmann L and Moreau NJ. A novel, double mutation in DNA Gyrase A of *Escherichia coli* conferring resistance to quinolone antibiotics. Antimicrobial Agents and Chemother 41:85-90, 1997.

85. Bonomo RA, Rice R, Whalen C, Linn D, Eckstein E and **Shlaes** DM. Risk factors associated with permanent access site infections in chronic hemodialysis patients. Infect Cont and Hosp Epidemiol, 18:757-761, 1997.

86. Miller GH, Sabatelli FJ, Hare RS, Glupczynski Y, Mackey P, **Shlaes** DM, Shimizu K, and Shaw KJ. Aminoglycoside resistance study groups: The most frequent aminoglycoside resistance mechanisms - Changes with time and geographic area - A reflection of aminoglycoside usage patterns? Clin Infect Dis 24Suppl 1:S46-S61, 1997.

87. Bonomo RA, Knox JR, Rudin S and **Shlaes** DM. Construction and Characterization of an OHIO-1 β-lactamase bearing Met69Ile-Gly238Ser substitutions. Antimicrobial Agents and Chemotherapy, 41:1940-3, 1997.

88. Higashi JM, Wang IW, **Shlaes DM**, Anderson JM and Marchant RE. Adhesion of *Staphylococcus epidermidis* and transposon mutant strains to hydrophobic polyethylene. Journal of Biomedical Materials Research 39:341-350, 1998.

89. Bonomo RA, **Shlaes** DM, Rudin S. Tazobactam is a potent inactivator of inhibitor-resistant Class A Beta-lactamases. FEMS Microbiology Letters 148: 59-62, 1997.

90. Billot-Klein D, **Shlaes** DM, Bryant D, Bell D, Gutmann L and Van Heijenhoort J. Presence of UDP-*N*-acetylmuramyl branched peptides in vacomycin-resistant enterococci and staphylococci after treatment with ramoplanin, tunicamycin or vancomycin. J. Bacteriol 179:4684-4688, 1997.

91. **Shlaes** DM, Gerding DN, John JF, Craig WA *et. al.* Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals. Infect. Control and Hosp Epidemiol 18:275-291, 1997. *Reprinted in* Clin Infect Dis 25:584-599, 1997.

92. Bonomo RA, Rudin SD and **Shlaes** DM. OHIO-1 β-lactamase Mutants: Asp179Gly mutation confers resistance to ceftazidime. FEMS Microbiol Lett 152:275-298, 1997.

93. Lin S, Thomas M, **Shlaes** DM, Rudin SD, Knox R, Anderson V and Bonomo RA. Kinetic analysis of an inhibitor resistant variant of the OHIO-1 β-lactamase, an SHV Family class A enzyme. Biochem J 333:395-400, 1998.

94. Yang Y-J, Janota K, Tabei K, Huang N, Siegel MM, Lin Y-I, Rasmussen BA and **Shlaes** DM. Mechanism of inhibition of the class A B-lactamases PC1 and TEM-1

by tazobactam: Observation of reaction products by electrospray ionization mass spectrometry. J Biol Chem 275:26674-82, 2000.

95. P.M. Dunman, E. Murphy, S. Haney, D. Palacios, G. Tucker-Kellogg, S. Wu, E.L. Brown, R.J. Zagursky, **D. Shlaes**, and S.J. Projan. Transcription Profiling-based identification of *Staphylococcus aureus* genes regulated by the *agr* and/or *sarA* loci. J. Bacteriol 183:7341-7353, 2001.

96. Alexey Ruzin, Anatoly Severin, Frank Ritacco, Keiko Tabei, Guy Singh, Patricia A. Bradford, Marshall M. Siegel, Steven J. Projan and David M. **Shlaes**. Further evidence that cell wall precursor [C55-MurNAc-(peptide)-GlcNAc] serves as an acceptor in sorting reaction. J Bacteriol, 184, 2141-2147, 2002.

97. Bouhss A., Josseaume N., Severin A., Tabei K., Hugonnet J-K., **Shlaes D.**, et. Al. Synthesis of the L-alanyl-L-alanine cross-bridge of *Enterococcus faecalis* peptidoglycan. J Biol Chem 277:45935-41, 2002.

98. Ruzin A, Severin A, Moghazeh SL, Etienne J, Bradford PA, Projan SJ and **Shlaes DM**. Inactivation of *mprF* affects vancomycin susceptibility in *Staphylococcus aureus*. Biochim Biophys Acta 1621: 117-21, 2003.

99. Ruzin A, Singh G, Severin A, Yang Y, Dushin R, Sutherland A, Minnick A, Greenstein M, May M, **Shlaes DM** and Bradford P. Mechanism of action of the mannopeptimycins, a novel class of glycopeptide antibiotics active against vancomycin-resistant Gram positive bacteria. Antimicrob Agents and Chemother 48:728-738, 2004.

100. Dushin RG, Wang TZ, Sum PE, He H, Sutherland AG, Ashcroft JS, Graziani EI, Koehn FE, Bradford PA, Petersen PJ, Wheless KL, How D, Torres N, Lenoy EB, Weiss WJ, Lang SA, Projan SJ, **Shlaes DM**, Mansour TS. Hydrophobic acetal and ketal derivatives of mannopeptimycin-alpha and desmethylhexahydromannopeptimycin-alpha: semisynthetic glycopeptides with potent activity against Gram-positive bacteria. J Med Chem. 2004 Jul 1;47(14):3487-90.

101. Aranapakam M. Venkatesan, Atul Agarwal, Takao Abe, Hideki Ushirogochi, Itsuki Yamamura, Toshio Kumagai, Peter J. Petersen, William J. Weiss, Eileen Lenoy, Youjun Yang, **David M. Shlaes**, John L. Ryan and Tarek S. Mansour. Novel imidazole substituted 6-methylidene-penems as broad-spectrum b-lactamase inhibitors. Bioorganic & Medicinal Chemistry 12 (2004) 5807–5817.

102. Youjun Yang, Anatoly Severin, Rajiv Chopra, Girija Krishnamurthy, Guy Singh, William Hu, David Keeney, Kristine Svenson, Peter J Petersen, Pornpen Labthavikul, **David M Shlaes**, Beth A Rasmussen, Amedeo A Failli, Jay S Shumsky, Kristina M K Kutterer, Adam Gilbert, Tarek S Mansour. 3,5-Dioxopyrazolidines, Novel Inhibitors of UDP-N- Acetylenolpyruvylglucosamine Reductase (MurB) with

Activity against Gram-Positive Bacteria. Antimicrob Agents Chemother. (2006) 50:556-64

103. Aranapakam M. Venkatesan,*,† Atul Agarwal,† Takao Abe,‡ Hideki Ushirogochi,‡ Itsuka Yamamura,‡ Mihira Ado,‡Takasaki Tsuyoshi,‡ Osvaldo Dos Santos,† Yansong Gu,† Fuk-Wah Sum,† Zhong Li,† Gerry Francisco,† Yang-I Lin,†Peter J. Petersen,§ Youjun Yang,§ Toshio Kumagai,‡ William J. Weiss,§ **David M. Shlaes**,§ James R. Knox,| andTarek S. Mansour.† Structure-Activity Relationship of 6-Methylidene Penems Bearing 6,5 Bicyclic Heterocycles as Broad-Spectrum *â*-Lactamase Inhibitors: Evidence for 1,4-Thiazepine Intermediates with C7 R Stereochemistry by Computational Methods. *J. Med. Chem.* **2006,** *49,* 4623-4637

104. Venkatesan AM, Agarwal A, Abe T, Ushirogochi H, Ado M, Tsuyoshi T, Dos Santos O, Li Z, Francisco G, Lin YI, Petersen PJ, Yang Y, Weiss WJ, **Shlaes DM**, Mansour TS. 5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of beta-lactamases. Bioorg Med Chem. 2007 Nov 5

105. David M. Shlaes and Robert. C. Moellering Jr. Telithromycin and the FDA: Implications for the Future. Lancet ID, 2008.

INVITED REVIEWS, CHAPTERS AND SYMPOSIA:

1. **Shlaes** DM and Bass SN. Combination antimicrobial therapy. Ped Clin N Amer 30:121-134, 1983.

2. **Shlaes** DM. Koneman et. al. Color Atlas and Textbook of Diagnostic Microbiology, second ed. 1984. Book review for Ann Intern Med 101:288-9, 1984.

3. **Shlaes** DM. Demystifying the streptococci. Diagnostic Med, 1985.

4. **Shlaes** DM and Currie-McCumber CA. Molecular epidemiology: Summary and future directions. Rev Infec Dis, 8:738-746, 1986.

5. **Shlaes** DM and Currie-McCumber CA. The Molecular Epidemiology of Antimicrobial Resistance. (Book chapter for volume entitled "Microbial Resistance to Drugs" edited by Dr. L. Bryan, Springer, 1989).

6. **Shlaes** DM. β–lactamase and β–lactam resistance. Tech Sample. Amer Soc Clin Pathol, Microbiol Tech Sample MB-1, 1986.

7. **Shlaes** DM. Considerations in the development of resistance. Chapter in mongraph entitled, "Infection: A complication of Surgery." Medical Education Programs, Ltd., 1987.

8. **Shlaes** DM. Antibiotic use and R-plasmids in a nursing home. Newsletter, AUPA, Fall, 1986.

9. **Shlaes** DM. Antibiotic Resistant Enterococci. Infectious Diseases Newsletter, 8:53-55, 1989.

10. **Shlaes**, DM. "The Miscellaneous Streptococci" Chapter in text, Infectious Diseases in Medicine and Surgery, ed. by Bartlett, Blacklow and Gorbach 1992.

11. **Shlaes** DM, Al-Obeid S and Gutmann L. Enterococcal Resistance to Cyclic Glycopeptides. APUA, Winter, 1990.

12. Binczewski B and **Shlaes** DM. Vancomycin-resistant Enterococci. Eur J Clin Microbiol, 9:106-110, 1990.

13. Bonomo R and **Shlaes** DM. Bacterial resistance to β−lactam-β−lactamase-inhibitor combinations. Infections In Medicine, 1992.

14. **Shlaes** DM. Vancomycin Resistant Bacteria. Editorial. Infect Control and Hosp Epidemiol 13:193-194,1992

15. **Shlaes** DM, Binczewski B and Rice LB. Emerging Antimicrobial Resistance and the Immunocompromised Host. CID 17(Suppl 2):S527-536, 1993.

16. **Shlaes** DM. Cost and public health implications of antibiotic resistance. FDA monograph, 1993.

17. **Shlaes** DM. Clinical Relevance of Enterobacter Infection. Clinical Therapeutics. 15 (SupplA):21-28, 1993.

18. **Shlaes** DM. Clinical importance and public health concerns for the emergence of antibiotic resistance in the human intestinal flora. Vet and Human Toxicol 35Suppl1:24-7, 1993.

19. **Shlaes** DM and Rice LB. Mechanisms of Antimicrobial Resistance for the Hospital Epidemiologist. Chapter for Textbook in Infection Control and Hospital Epidemiology edited by C. Glenn Mayhall. 1995.

20. Rice LB and **Shlaes** DM. Mechanism of Vancomycin Resistance: Relevance for Pediatrics. Pediatric Infec Dis Clin of NA, 42:601-18, 1995.

21. **Shlaes** DM and Rice LB. Emerging Mechanisms of Resistance to β-lactam Antibiotics. Infect Dis in Clin Pract, 4(S1):S175-S186, 1995.

22. **Shlaes** DM and Rice LB. Mechanism of resistance to glycopeptide antibiotics in enterococci. Trends in Microbiol, 2:385-8, 1994.

23. Fraimow HS. **Shlaes** DM. Glycopeptide resistance in gram-positive pathogens. Advances in Experimental Medicine & Biology.390:81-95, 1995.

24. **Shlaes**, DM and Zabransky RJ. "The Miscellaneous Streptococci" Chapter in text, Infectious Diseases in Medicine and Surgery, ed. by Bartlett, Blacklow and Gorbach 1997.

25. Chow JW and **Shlaes DM**. *Enterococcus spp.* In Antimicrobial Therapy and Vaccines, ed. Yu VL, Merigan TC and Barriere SL. Williams & Wilkins, Baltimore, 1999.

26. Yang Y-J, Rasmussen BA and **Shlaes** DM. Class A B-lactamases – enzyme-inhibitor interactions and resistance. Pharmacology and Therapeutics 83:151-51, 1999.

27. **Shlaes DM**. Respiratory Syncytial Virus Infection: An emerging or unappreciated infection? Sem in Respir and crit care med 21:305-311, 2000.

28. **Shlaes DM**., Ryan John L. Strategic and Regulatory considerations in the development of anti-infective drugs, in Drugs in Clinical Development Eds. Norrby, Whitley et. al., 2002.

29. **Shlaes DM**, Moellering RC Jr.. The United States Food and Drug Administration and the End of Antibiotics. Letter, Clin Infect Dis 34:420-22, 2002.

30. **Shlaes DM**. Reply to Letter, Is there hope for the prevention of future antimicrobial shortages? Clin Infect Dis 35:216, 2002.

31. **Shlaes DM** The abandonment of antibacterials: why and wherefore? Curr Opin Pharmacol. 2003 Oct;3(5):470-3.

32. **Shlaes DM**, Projan SJ and Edwards J. Antibiotic Discovery: State of the State, ASM News, June, 2004

33. Projan SJ and **Shlaes DM**. Antibacterial Drug Discovery: Is it all downhill from here? Clin Microbio and Infect Dis, 2004.

34. **Shlaes DM.** Tetracyclines: An Update. Curr Opin Investig Drugs. 2006 Feb;7(2):167-71.

35. **Shlaes DM**, Alksne L and Projan SJ. The Pharmaceutical Industry and Inhibitors of Bacterial Enzymes: Implications for Drug Development. Book Chapter, ASM Press, 2007.

36. **Shlaes DM.** New Antibiotics – Government Intervention vs. Market Forces. Forum. Microbe, Feb. 2007.

37. Novak R and **Shlaes DM**. The pleuromutilin antibiotics: New compounds for human use**.** Current Opinion in Investigational Drugs. 2010. 11:182-91

REPORTS FROM THE INSTITUTE OF MEDICINE FORUM ON EMERGING INFECTIONS, NATIONAL ACADEMY OF SCIENCES:

1. Orphans and Incentives, Developing technologies to address emerging infections. National Academy Press, 1997.

2. Antimicrobial Resistance, Issues and options. National Academy Press, 1998.

3. Managed Care Systems and Emerging Infections, Challenges and opportunities of strengthening surveillance, research and prevention. National Academy Press, 2000.

4. Public Health Systems and Emerging Infections, Assessing the capabilities of the public and private sectors. National Academy Press, 2001.

5. Emerging Infectious Diseases from the Global to the Local Perspective. National Academy Press, 2001.

6. Biological Threats and Terrorism. National Academy Press, 2002.

7. The Resistance Phenomenon in Microbes and Infectious Disease Vectors: Implications for Human Health and Strategies for Containment -- Workshop Summary. National Academy Press, (2003)